http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 14:40:06 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Options/LakeShore+Biopharma+%28LSB%29+3400+contracts+of+August+12.50+calls/26807471.html <p>LakeShore Biopharma (NASDAQ: LSB) 30-day call option implied volatility is 57; compared to its 52-week range of 30 to 89 with a focus on 3400 contracts of August 12.50 calls. </p> http://www.streetinsider.com/Options/LakeShore+Biopharma+%28LSB%29+3400+contracts+of+August+12.50+calls/26807471.html Thu, 23 Jul 2026 14:40:06 -0400 LSB http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Sep+22/25358569.html si-local-file:///var/storage/secattach/20250922/25358569.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Sep+22/25358569.html Mon, 22 Sep 2025 08:10:00 -0400 LSB O.50653405 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Sep+22/25358569.html si-local-file:///var/storage/secattach/20250922/25358569.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Sep+22/25358569.html Mon, 22 Sep 2025 08:10:00 -0400 LSB O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that effective with the opening of business today, <chron>September 22, 2025</chron>, the Company's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq").</p> <p>On the same day, the Company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html Mon, 22 Sep 2025 08:00:00 -0400 LSB LSBCF LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that effective with the opening of business today, <chron>September 22, 2025</chron>, the Company's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq").</p> <p>On the same day, the Company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html Mon, 22 Sep 2025 08:00:00 -0400 LSB LSBCF LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that effective with the opening of business today, <chron>September 22, 2025</chron>, the Company's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq").</p> <p>On the same day, the Company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html Mon, 22 Sep 2025 08:00:00 -0400 LSB LSBCF LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that effective with the opening of business today, <chron>September 22, 2025</chron>, the Company's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq").</p> <p>On the same day, the Company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html Mon, 22 Sep 2025 08:00:00 -0400 LSB LSBCF LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that effective with the opening of business today, <chron>September 22, 2025</chron>, the Company's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq").</p> <p>On the same day, the Company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html Mon, 22 Sep 2025 08:00:00 -0400 LSB LSBCF LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that effective with the opening of business today, <chron>September 22, 2025</chron>, the Company's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq").</p> <p>On the same day, the Company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html Mon, 22 Sep 2025 08:00:00 -0400 LSB LSBCF LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that effective with the opening of business today, <chron>September 22, 2025</chron>, the Company's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq").</p> <p>On the same day, the Company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html Mon, 22 Sep 2025 08:00:00 -0400 LSB LSBCF LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that effective with the opening of business today, <chron>September 22, 2025</chron>, the Company's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq").</p> <p>On the same day, the Company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html Mon, 22 Sep 2025 08:00:00 -0400 LSB LSBCF LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that effective with the opening of business today, <chron>September 22, 2025</chron>, the Company's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq").</p> <p>On the same day, the Company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html Mon, 22 Sep 2025 08:00:00 -0400 LSB LSBCF LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that effective with the opening of business today, <chron>September 22, 2025</chron>, the Company's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq").</p> <p>On the same day, the Company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html Mon, 22 Sep 2025 08:00:00 -0400 LSB LSBCF LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that effective with the opening of business today, <chron>September 22, 2025</chron>, the Company's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq").</p> <p>On the same day, the Company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html Mon, 22 Sep 2025 08:00:00 -0400 LSB LSBCF LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 22, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that effective with the opening of business today, <chron>September 22, 2025</chron>, the Company's ordinary shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq").</p> <p>On the same day, the Company's ordinary shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Transition+to+OTC+Market+Following+Nasdaq+Delisting/25358336.html Mon, 22 Sep 2025 08:00:00 -0400 LSB LSBCF LSBCF LSBWF LSBWF O.50653405 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Sep+12/25327954.html si-local-file:///var/storage/secattach/20250912/25327954.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Sep+12/25327954.html Fri, 12 Sep 2025 09:05:00 -0400 LSB O.50653405 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Sep+12/25327954.html si-local-file:///var/storage/secattach/20250912/25327954.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Sep+12/25327954.html Fri, 12 Sep 2025 09:05:00 -0400 LSB O.50653405 http://www.streetinsider.com/Corporate+News/LakeShore+Biopharma+faces+Nasdaq+delisting+after+bid+price+violation/25327622.html <p>LakeShore Biopharma Co., Ltd. (NASDAQ: LSB) received a delisting determination letter from Nasdaq Stock Market LLC dated September 11, 2025, according to a company announcement.</p><p>The Beijing-based biopharmaceutical company violated Nasdaq Listing Rule 5550(a)(2) after its closing bid price remained below $1.00 per share for 30 consecutive business days. The company is not eligible for the standard 180-day compliance period because it completed a 10-for-1 reverse stock split on October 1, 2024.</p><p>Under Nasdaq Listing Rule 5810(c)(3)(A)(iv), companies that have executed a reverse stock split within the prior year are ineligible for any compliance period. Trading in LakeShore Biopharma securities will be http://www.streetinsider.com/Corporate+News/LakeShore+Biopharma+faces+Nasdaq+delisting+after+bid+price+violation/25327622.html Fri, 12 Sep 2025 08:00:50 -0400 LSB http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+Delisting+Determination+Letter+from+Nasdaq/25327617.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 12, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it received a staff determination letter (the "Letter") from the <span>Nasdaq Stock Market LLC</span> ("Nasdaq"), dated <chron>September 11, 2025</chron>, notifying that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") because the closing bid price for the Company's ordinary shares was below http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+Delisting+Determination+Letter+from+Nasdaq/25327617.html Fri, 12 Sep 2025 08:00:00 -0400 LSB O.50653405 http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+Delisting+Determination+Letter+from+Nasdaq/25327617.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 12, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it received a staff determination letter (the "Letter") from the <span>Nasdaq Stock Market LLC</span> ("Nasdaq"), dated <chron>September 11, 2025</chron>, notifying that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") because the closing bid price for the Company's ordinary shares was below http://www.streetinsider.com/Press+Releases/LakeShore+Biopharma+Announces+Receipt+of+Delisting+Determination+Letter+from+Nasdaq/25327617.html Fri, 12 Sep 2025 08:00:00 -0400 LSB O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+Delisting+Determination+Letter+from+Nasdaq/25327617.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 12, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it received a staff determination letter (the "Letter") from the <span>Nasdaq Stock Market LLC</span> ("Nasdaq"), dated <chron>September 11, 2025</chron>, notifying that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") because the closing bid price for the Company's ordinary shares was below http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+Delisting+Determination+Letter+from+Nasdaq/25327617.html Fri, 12 Sep 2025 08:00:00 -0400 LSB O.50653405 http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+Delisting+Determination+Letter+from+Nasdaq/25327617.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>Sept. 12, 2025</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LSB" idsrc="xmltag.org" >LakeShore Biopharma Co., Ltd</span> (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it received a staff determination letter (the "Letter") from the <span>Nasdaq Stock Market LLC</span> ("Nasdaq"), dated <chron>September 11, 2025</chron>, notifying that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") because the closing bid price for the Company's ordinary shares was below http://www.streetinsider.com/PRNewswire/LakeShore+Biopharma+Announces+Receipt+of+Delisting+Determination+Letter+from+Nasdaq/25327617.html Fri, 12 Sep 2025 08:00:00 -0400 LSB O.50653405 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Sep+10/25318288.html si-local-file:///var/storage/secattach/20250910/25318288.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Sep+10/25318288.html Wed, 10 Sep 2025 08:59:00 -0400 LSB O.50653405 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Sep+10/25318288.html si-local-file:///var/storage/secattach/20250910/25318288.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++LakeShore+Biopharma+Co.%2C++For%3A+Sep+10/25318288.html Wed, 10 Sep 2025 08:59:00 -0400 LSB O.50653405 http://www.streetinsider.com/Corporate+News/LakeShore+Biopharma+appoints+advisors+for+takeover+proposal+review/25317979.html <p>LakeShore Biopharma Co., Ltd. (NASDAQ: LSB) announced that its independent special committee has retained financial and legal advisors to evaluate a preliminary non-binding takeover proposal received on August 26, 2025.</p><p>The Beijing-based biopharmaceutical company said the special committee appointed Kroll, LLC as financial advisor, Gibson, Dunn & Crutcher LLP as U.S. legal counsel, and Maples and Calder (Hong Kong) LLP as Cayman Islands legal counsel.</p><p>The special committee continues reviewing the proposal, according to the company's statement. LakeShore Biopharma cautioned shareholders that no decisions have been made regarding the proposal and provided no assurance that a definitive offer will be received or http://www.streetinsider.com/Corporate+News/LakeShore+Biopharma+appoints+advisors+for+takeover+proposal+review/25317979.html Wed, 10 Sep 2025 08:10:33 -0400 LSB